ARCHIVES

Clinical Societies, Patient Groups Need New Alliance, Glick Proposes to ASCO

This article is from The Cancer Letter archive.

Vol. 22 No. 21 | May 24, 1996

Download PDF Visit The Full Archive

Related Articles

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

March 28, 2014

Cancer Centers Form Network To Compete For Managed Care, Develop Standards

January 27, 1995

NCAB Approves New Grant Award Honoring Howard Temin

March 8, 1996

Efaproxyn Improved Survival Of Patients With Brain Mets

October 29, 2004

ASCO and CAP Issue Guideline To Improve HER2 Testing

October 25, 2013

CCIRC Told Group Radiation Studies Cost $20,000 Per 25 Patients

March 14, 1980